All News

In this article, Robert A. Dowling, MD, describes some of the important differences and practical aspects of Stage 2 meaningful use as they related to "eligible professionals."

Products and services in the pipeline from Nymox Pharmaceuticals Corp.; OncoGenex Pharmaceuticals, Inc.; Ampio Pharmaceuticals, Inc.; Aragon Pharmaceuticals; Sophiris Bio Inc.; Genomic Health, Inc.; OxThera AB; Aeterna Zentaris Inc.; and Tengion, Inc.

Photoselective laser vaporization of the prostate performed prior to external beam radiation therapy appears to be a viable approach for managing symptomatic BPH in men with concomitant prostate cancer, according to the findings of a retrospective study.

A screening protocol to guide antibiotic prophylaxis prior to prostate biopsy that eliminates the broth enrichment provides the best sensitivity with the fewest false- positive rates.

If a nephrostomy tube removal is performed in conjunction with another service, such as an evaluation and management service, you should either report the other service(s) documented and consider the nephrostomy tube removal incidental or add a –22 to the other service if documentation supports a significant increase in effort.

The latest products and services from Ethicon Endo-Surgery, InSightec Ltd., Watson Pharmaceuticals, Coloplast, Envaste Ltd., Cardinal Health, Medline Industries, Inc., and DocBookMD.

Here are some problems delayed billing present and how you can avoid them.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes phase II, III, and IV urinary incontinence trials that are currently recruiting participants.

Men with moderate to severe lower urinary tract symptoms associated with BPH obtained significant symptom relief with the phosphodiesterase type-5 inhibitor tadalafil (Cialis) and the alpha-blocker tamsulosin (Flomax), both of which also improved urinary flow, results of a randomized trial showed.

In this interview, Barry A. Kogan, MD, discusses the status of advanced practice practitioners in urology, their education, training, and scope of practice.

On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.

Primary therapy for prostate cancer does not reduce the frequency of end-of-life urologic procedures, according to the findings of a population-based study.

Urologists discuss whether burnout affects them and, if so, what they do to cope.

Here are some resources regarding laws and regulations governing nurse practitioners and physician assistants in your state.

Urologist Catherine R. deVries, MD, has been named a recipient of the American College of Surgeons 2012 Surgical Humanitarian Award.

Uroplasty, Inc. recently announced an expansion of coverage of percutaneous nerve stimulation (PTNS) using its Urgent PC neuromodulation system for the treatment of symptoms of overactive bladder syndrome.

Men with prostate cancer who consumed green tea prior to undergoing prostatectomy had reductions in markers of inflammation, say researchers from UCLA’s David Geffen School of Medicine.

The method of toilet training chosen by parents has no bearing on urinary accidents in children, new research shows.

Patients undergoing treatment for prostate cancer using proton beam therapy reported a higher quality of life in early follow-up but similar QoL scores at 2 years compared to 3-D conformal and intensity-modulated radiation therapy, according to a new study.

Join Urology Times and Contemporary Pediatrics for a discussion about controversies over circumcision and its implications.

Astellas Pharma US, Inc. has announced that mirabegron (Myrbetriq), indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, is now available through U.S. pharmacies.

As a result of concerns about antibiotic resistance, U.S. physicians are increasingly prescribing quinolones to treat urinary tract infections.

Researchers from Mount Sinai School of Medicine in New York say they have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer.

Components of metabolic syndrome have been jointly linked with an increased risk of dying from prostate cancer, according to a recent study.

Chesapeake Urology Associates of Owings Mills, MD and Jersey Shore University Medical Center in Neptune, NJ have announced the appointment of new urologists to their respective practices.

A neobladder reconstruction technique that is performed using robotic assistance appears to be a safe, less invasive option in patients with aggressive bladder cancer.

Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.

Data from a phase III study have linked the advanced prostate cancer drug abiraterone acetate (ZYTIGA) to delayed pain progression and functional decline in a certain subset of advanced prostate cancer patients.